Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05200364
Title A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
Recruitment Recruiting
Gender female
Phase Phase I
Variant Requirements No
Sponsors Sutro Biopharma, Inc.
Indications

ovarian cancer

peritoneum cancer

fallopian tube cancer

Therapies

Bevacizumab + STRO-002

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.